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The study of new biologically active molecules for the understanding of the cellular 
functioning is essential for the advancement of modern medicine. This project is focused on the 
synthesis of the (2S,3S,E)-ceramide-1,3-phosphodiester, a synthetic molecule inspired by three 
molecules with a determinant role in the life cycle of animal cells: ceramide, ceramide-1-
phosphate and the corresponding cyclic phosphate. Slight changes into the structures of the 
mentioned molecules may change, and even invert their cellular role. Therefore, and 
considering that the biological function is very dependent on the structural changes, it has been 
decided to carry out the insertion of a cyclic phosphodiester into the ceramide backbone, as well 
as the change to a non-natural (2S,3S) configuration instead of the natural (2S,3R), while 
maintaining the E configuration of the double bond. 
Keywords: (2S,3S,E)-ceramide-1,3-phosphodiester, stereoselective synthesis, cellular role. 
 




L’estudi de noves molècules biològicament actives per a la comprensió del funcionament 
cel·lular és imprescindible per a l’avenç de la medicina moderna. Aquest projecte està enfocat a 
la síntesi de la (2S,3S,E)-ceramida-1,3-fosfodiester, una molècula sintètica inspirada en tres 
molècules amb un rol determinant al cicle de vida cel·lular animal: la ceramida, la ceramida-1-
fosfat i el corresponent fosfat cíclic. Petits canvis a les estructures de les molècules 
esmentades poden canviar, i inclús invertir el rol cel·lular d’aquestes. Per això, i atès que la 
funció biològica és molt depenent dels canvis estructurals, s’ha decidit dur a terme la inserció 
d’un diéster fosfòric cíclic a la ceramida, així com el canvi a la configuració no natural (2S,3S) 
enlloc de la natural (2S,3R), tot mantenint la configuració E del doble enllaç.  
 
Paraules clau: (2S,3S,E)-ceramida-1,3-fosfodiester, síntesi estereoselectiva, rol cel·lular. 




Naturally, our cells control their population by apoptosis, also called programmed cell death, 
which is a procedure that intervenes in 
the tissue homeostasis through which 
the cells inactivate and degrade their 
own structure and components until 
death.1 The integrity of plasma 
membrane is preserved until the end of 
the process, allowing the organelles 
packaging. These will be disintegrated 
into vesicles attached to the membrane, 
avoiding the release of toxic intracellular 
components to the outside. The cell 
fragments will be phagocytosed by 
macrophages or neighboring cells, thus 
the tissue damage will be avoided. 
Consequently, normal development 
remains under control and the 
elimination of unnecessary cells is 
carried out. Cellular apoptosis is strongly 
linked to diseases such as cancer, 
inasmuch as the malignant cells evade 
apoptotic mechanisms, thus causing an indiscriminate proliferation of the cells with the 
consequent formation of the tumor.1 For this reason, the study and use as biomarkers of both 
the molecules involved in the apoptosis and cell proliferation processes are of vital importance 
to advance in research and improvement of new therapies and prevention. Among these 
biomolecules it is included ceramides, which have an apoptotic role.2 The most common 
Figure 1: Natural and synthetic ceramides  
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ceramides are those that are formed by sphingosine amide-bonding to a fatty acid with usually 
16-24 carbons.1 These long fatty acids make ceramide have a hydrophobic character, since the 
hydrophilic region of the molecule (only formed by two hydroxyl groups) is minimal. However, it 
can change with the phosphate insertion in the molecule, making (2S,3S,E)-ceramide-1,3-
phosphodiester less polar than the natural phosphate. In addition to a structural function in the 
cell lipid bilayer, ceramides also play the role of second messengers in cellular division acting as 
a differentiation messenger, in permeation of membranes, senescence, cell signaling, and as 
insulin suppressant.3  But it is worth noting that ceramides have an extremely key role in 
apoptotic pathways: A very sensitive balance has been established between ceramide-1-
phosphate, ceramide, sphingosine, and sphingosine-1-phosphate within the cell, which are 
easily interconverted.1,2  
The intracellular balance of these four sphingolipids, usually referred as “sphingolipid rheostat”, 
will determine the survival of the cell, where ceramide and sphingosine increase cell apoptosis, 
and sphingosine-1-phosphate and ceramide-1-phosphate are involved in cell proliferation and 
survival.3 This balance occurs naturally in all mammal cells, but can be affected by ionizing 
radiation, ultraviolet C radiation, stress and others, causing the unbalance of the sphingolipid 
rheostat.1,2 Minor changes in the structure of these molecules, as for example the addition of a 
cyclic phosphate in its primary hydroxyl group, or changing the natural configuration (2S,3R) to 
the non-natural (2S,3S), can cause the molecule carry out a completely different role within the 
Scheme 1: Sphingolipid rheostat 
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cell.  Therefore, although the ceramides have a major apoptotic function, the role of (2S,3S,E)-
ceramide-1,3-phosphodiester within the cell (the synthetic target of this project) is difficult to 
predict. Even so, it would be interesting to know the biological behavior of this molecule, due to 
its structural similarity to molecules such as natural ceramides like (2S,3R)-ceramide-1-
phosphate and cyclic phosphodiester,4 both with a biologically active role.1,3 So, the new 
molecule could have an interesting therapeutic application; currently, ceramides are already 
used as inhibitors of cell proliferation in cancer therapies, for example, treatments as used as 
chemotherapy or radiotherapy increases cell's ceramide concentration. 
The fact of finding the cyclic phosphates of ceramide5 in nature opens a way to study their 
biological activity, both natural and synthetic ceramides. (2S,3R,E)-Ceramide-1,3-
phosphodiester (9) was previously prepared by the research group. In this project a new 
synthetic approach will be designed to obtain the (2S,3S,E)-ceramide-1,3-phosphodiester (3). 
Finally, the resulting (2S,3S,E) ceramide phosphodiester will be tested in cell models and 
compared with the previously obtained (2S,3R,E) isomer.  
  
Figure 2: (2S,3S,E) and (2S,3R,E) ceramides-1,3-phosphodiester 




The main objective of this project is to carry out the synthesis of the (2S,3S,E)-ceramide-
1,3-phosphodiester (3), starting from Garner's aldehyde6 (10) taking care of the (2S,3S) and E 
configurations of the different intermediates. These will be characterized by means of different 
spectroscopic techniques, like mono and bidimensional 1H NMR (COSY and HSQC), 13C NMR 
and 31P NMR. The synthetic approach can be divided into minor objectives, as follows: 
• The stereoselective C-C bond formation to create the alcohol with S configuration with an 
organometallic reagent. 
• N-Boc and N,O-isopropylidene deprotection. 
• N-acylation with palmitic acid. 
• Phosphorylation of the C1 (or C3) hydroxyl group. 
• (In the phosphorus(III) synthetic route, oxidization from hydrogenphosphonate to 
phosphonate). 









Scheme 2: Schematic synthetic approach 




4.1. RETROSYNTHETIC ANALYSIS  
The proposed retrosynthetic analysis in order to obtain the (2S,3S,E)-ceramide-1,3-
phosphodiester (3) is represented in the Scheme 3. It was planned to use an organometallic 
reagent to carry out the addition of the carbon chain through the syn-selective addition to the 
aldehyde, obtaining the desired allylic alcohol with the S configuration. Once formed, it was 
supposed to do the simultaneous deprotection of the Boc and the N,O-isopropylidene acetal by 
an acidic medium, followed by the N-acylation with palmitic acid using HOBt and EDC, leading 
to the formation of (2S,3S,E)-ceramide (13). At this point, in order to reach the synthetic target 
3, it has been decided to test two possible synthetic routes. In the first approach, it has been 
decided to add an hydrogenphosphonate group to the C1 (or C3) alcohol of the ceramide 13 
affording the compound 16, finishing the synthetic route with the oxidation from 
hydrogenphosphonate to phosphonate and its subsequent cyclization with tert-butyl 
hydroperoxide. On the other hand, through the phosphorus(V) pathway, it has been decided to 
do the formation of a dimethyl phosphate on the C1 (or C3) hydroxyl group by the addition of 
dimethyl chlorophosphate, followed by its deprotection using TMSI. Finally, the cyclization of 15 
with N,N-dicyclohexylcarbodiimide (DCC) would afford the desired compound. 
 
  




Scheme 3: Retrosynthetic analysis 




5. RESULTS AND DISCUSSION 
5.1. STEREOSELECTIVE ADDITION OF THE ORGANOMETALLIC REAGENT TO THE 
GARNER’S ALDEHYDE: SYNTHESIS OF TERT-BUTYL (S)-4-[(S,E)-1-HYDROXYHEXADEC-
2-EN-1-YL]-2,2-DIMETHYLOXAZOLIDINE-3-CARBOXYLATE  (11) 
According with T. Murakami and K. Furusawa,8 the new stereocenter configuration can be 
decided according to scheme 4. The stereoisomer anti-(2S,3R) can be obtained by the reaction 
of the complexation adduct 19 with Garner’s aldehyde (10) through zinc bromide in THF, while 
the syn-(2S,3S) adduct 11 can be obtained by the reaction of Garner’s aldehyde with the 
transmetallation adduct 21, the product of the reaction by diethyl zinc with the complexation 
adduct 19. This complexation adduct is the result of the reaction of the Schwartz reagent7 (18) 
with 1-pentadecyne (17). In general, the hydrozirconation with the Schwartz reagent7 proceeds 
rapidly, and more importantly, the former reaction tolerates the presence of certain functional 
groups, such as alkyl ethers, silyl ethers, and t-butyl esters. Although addition of 
alkenylzirconocenes to aldehydes is sluggish, the reaction is accelerated either by adding a 
catalyst or by transmetallation with dialkylzinc to afford (E)-allylic alcohols in acceptable yields.8 
The reaction mechanism of the zinc bromide catalyzed addition of alkenylzirconocenes remains 
unclear, and the syn-selective addition of pentadecyne-Zn in CH2Cl2 can be explained by a 
chelated transition model of Garner's aldehyde (10) with zinc or by a coordinated delivery 
model.8  
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The addition of 1-pentadecyne to Schwartz reagent was run at rt. After 20 min, a change in 
the coloration of the transparent solution from colorless to yellowish and the TLC control were 
evidenced the formation of the alkenylzirconium reagent 19. Then, diethylzinc was added at -
30ºC in order to do the transmetallated adduct. Finally, Garner’s aldehyde was added to the 
reaction mixture and the reaction stirred for 1 h at rt. After an aqueous work-up, a white 
precipitate of zirconium salts was observed. Once filtered with celite, a yellow organic solution 
corresponding to the addition compound 11 was observed. After a chromatographic purification 
of the crude reaction mixture two diastereoisomers of 11 could be isolated in 78% yield in a 94:6 
ratio by NMR, in agreement with related literature precedents8.  
 
Scheme 4: Diastereodivergent synthesis of N-Boc sphingosine derivatives from 10 and alkenyl-zirconocenes 8 













5.2. SYNTHESIS OF (2S,3S,E)-1,3-DIHYDROXYOCTADEC-4-EN-2-AMMONIUM 
CHLORIDE (12)  
 
The deprotection reaction was run by an acidic medium (HCl) for 48 h at room temperature. 






The N-Boc and N,O-isopropylidene deprotection of 12 was achieved by the generation of 
hydrochloric acid by the reaction of methanol with acetyl chloride, as indicated in the scheme 7. 
Scheme 7: Generation of HCl from MeOH and CH3COCl 
Scheme 5: Synthesis of 11   
Scheme 6: Deprotection of 11  
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5.3. SYNTHESIS OF (2S,3S)-CERAMIDE (13) 
The synthesis of ceramide 13 was carried out by N-acylation of 12 with palmitic acid in 
CH2Cl2 in presence of EDC (25) and HOBt (27) at room temperature, based on precedents of 
the RUBAM research group. This reaction may be conditioned by the high reactivity of the 
primary and secondary hydroxyl groups of the starting sphingosine or the resulting ceramide, 
which would complicate the reaction outcome. Both the primary and the secondary hydroxyl 
groups are not exempt from reacting, being able to give the formation of the corresponding 
palmitates. These esters could be saponified in basic medium, but this would suppose an 
additional reaction step and the probable loss in overall yield. In contrast, ceramide ester 
formation in the presence of EDC/HOBt has shown to be marginal (see the mechanism in 
Scheme 9).  
 
On the work up, the organic phase was washed three times with water. These water 
washings are required to remove the HOBt (27), the N-dimethylaminopropil N-ethyl urea 
(derived from EDC) (29) and other possible water-soluble impurities. It is advisable to not 
adding an excess of palmitic acid, due to the objective is to bonding it with the amine to forming 
amide, but an excess can make bond palmitic acid to the hydroxyl groups, forming an (COCOR) 
groups. Part of ceramide 13 eluted the column together with different esters of 13. Those esters 
were saponified with K2CO3 in MeOH at rt for 3 h. Next, the methanol was removed in vacuo, 
and the amide 13 resulting from the saponification reaction was purified. After purification, the 
ceramide 13 was obtained in 45% yield.  
 
 
Scheme 8: N-Acylation of 12 
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On the scheme 9, it can be observed the reaction mechanism of the EDC and the HOBt for 
the formation of the HOBt-palmitic acid intermediate adduct.  
 
On the scheme 10, it is described the mechanism by which the palmitic acid adds to the 











Scheme 9: Mechanism of the formation of the intermediate HOBt-palmitic acid 
Scheme 10: Formation of (2S,3S,E)-ceramide (13)  
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5.4. SYNTHESIS OF THE PHOSPHORYLATED CERAMIDES9 
Three kinds of phosphorus reagents are the most frequently used in the synthesis of 
phosphate esters: tetracoordinated phosphates with an oxidation state +5, tricoordinated 
phosphites (or phosphoramidites) with oxidation state +3, and tetracoordinated 
hydrogenphosphonates with an oxidation state +3. Phosphates have tetrahedral geometry and 
their chemistry is dominated by the presence of a very stable phosphoryl group (P=O). The 
phosphorus atom in tetracoordinated phosphates with an oxidation state +5, it is an electrophilic 
centre and it is subject to reactions with hard nucleophiles. On the contrary, phosphites and 
phosphoramidites have a trigonal pyramidal geometry with a lone electron pair located on the 
phosphorus atom. In general, phosphorus(III) derivatives can be easily converted into 
phosphorus(V) derivatives using different oxidizing reagents (e.g. iodine/water, elemental 















Figure 3: Phosphorus(III) and phosphorus(V) oxidation states  
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5.4.1. Synthesis of 3 via phosphorus(III) 
In order to reach the synthetic target 3 by the phosphorus(III) synthetic pathway it has been 
decided to add an hydrogenphosphonate group to the C1 alcohol of the ceramide 13 affording 
to the ammonium phosphonate 16, finishing the synthetic route with the oxidation with tert-butyl 
hydroperoxide from hydrogenphosphonate to phosphonate and its subsequent cyclization. 
 
5.4.1.1. Hydrogenphosphonate addition to the hydroxyl group: Synthesis of (2S,3S,E)-3-
hydroxy-2-palmitamidooctadec-4-en-1-yl phosphonate (16) 
 
For the addition of the hydrogen phosphonate, it is necessary to add a large excess of 
phosphorus trichloride to ensure its addition into the molecule. The tris(imidazol-1-yl)phosphine 
formed by the reaction of PCl3 with imidazole can be bonded to both primary or secondary 
hydroxyl groups, always being bonded only to one of them. Whether it is in the primary hydroxyl 
or in the secondary hydroxyl group is irrelevant, given the nature of the next reaction step: the 
cyclization. The method used to prevent the phosphorus bonding in both hydroxyl groups has 
been the addition of imidazole, which replaced the three chloride bonds by three imidazole 
bonds, causing steric effect for the unreacted hydroxyl group. When water was added at the end 
of the reaction, the imidazole groups were substituted forming the hydrogenphosphonate. The 
Scheme 11: Phosphorus(III) synthetic pathway 
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reaction was run at 0 ºC due to the truculence and the high reactivity of the phosphorus 
trichloride and left to react during 1.25 h warming gradually until room temperature. After 
purification, the phosphonate 16 was isolated in 80% yield. The 1H NMR and the 31P NMR 
showed that the hydrogenphosphonate was only added in the C1 carbon. 
 
 
5.4.1.2. Cyclization with pivaloyl chloride: Synthesis of N-[(4S,5S)-2-hydroxy-2-oxido-4-((E)-
pentadec-1-en-1-yl)-1,3,2-dioxaphosphinan-5-yl]palmitamide (3) 
 
The reaction of 16 with pivaloyl chloride and pyridine formed a phosphorous carboxylic 
anhydride, which could receive the attack of the alcohol to form the hydrogen phosphonate. In 
this way, the tert-butyl hydroperoxide could cyclize the phosphonate forming the diester bond, 
thus affording the synthetic target 3. After the addition of tert-butyl hydroperoxide, the reaction 
mixture was dried with MgSO4 and washed 3 times with a triethylamine:water solution to extract 
the pyridinium chloride salts. The reaction adduct was situated in the organic phase, instead of 
the aqueous. The synthesis procedure did not afford the desired compound 3. Traces of an 
unknown compound were isolated. This compound presented two peaks in 31P NMR at 4.86 
and 3.43 ppm, instead of one peak around zero that we expected.  
 
Scheme 13: First assessment of the cyclization reaction of 16  
Scheme 12: Synthesis of phosphonate 16  




5.4.2. Synthesis of 3 via phosphorus(V)  
In order to reach the synthetic target 3 by the phosphorus(V) synthetic pathway it has been 
decided to do the formation of a dimethyl phosphate on the C1 hydroxyl group by the addition of 
dimethyl chlorophosphate, followed by its deprotection using TMSI. Finally, the cyclization of 15 




5.4.2.1. Addition of dimethyl phosphate to the primary hydroxyl group of the ceramide: 
Synthesis of (2S,3S,E)-3-hydroxy-2-palmitamidooctadec-4-en-1-yl dimethyl phosphate (14) 
 
The reaction of diol 13 with dimethyl chlorophosphate in the presence of N-methylimidazole 
was run in CH2Cl2 at 0 ºC. After the reaction mixture was stirred for 10 min, it was observed a 
change of the yellowish reaction mixture from opaque to transparent. The TLC control did not 
show the presence of starting material 13. It was necessary to quenching the reaction the 
sooner the better, due to it was observed that impurities were formed over time. After the 
solution was quenched by water, the solution took whitish coloring. After purification the 
phosphate 14 was isolated in 61% yield. The 1H NMR showed that the dimethylphosphate was 
only added in the C1 carbon. 
 
Scheme 14: Phosphorus(V) synthetic pathway 








5.4.2.2. Deprotection of phosphate: Synthesis of (2S,3S,E)-3-hydroxy-2-
palmitamidooctadec-4-en-1-yl dihydrogen phosphate (15) 
 
The phosphate 14 was treated with TMSI in acetonitrile at 0°C. As the reaction progressed, 
it was observed a change in the coloration from yellow to orange, due to the presence of iodine 
in the reaction mixture. The iodine could produce the loss of the E-configuration of the double 
bond. To solve it, it was decided to add sodium thiosulfate to reduce the iodine to iodide. This 
reduction made the solution whitish, evidencing the complete elimination of iodine in the 
solution. Finally, it was added HCl 0.1 M to remove the SiMe3 group of the phosphonate 
changing it by a hydrogen group, forming SiMe3Cl and the phosphonate group. Unfortunately, 




Scheme 15: Formation of the dimethyl phosphate on the C1 hydroxyl group of 13 
Scheme 16: Deprotection of the dimethylphosphate 14 
 




6. EXPERIMENTAL SECTION 
6.1. MATERIALS AND METHODS 
6.1.1. Reagents and solvents: 
Unless otherwise specified, reactions were conducted in oven-dried glassware under inert 
atmosphere of argon with anhydrous solvents, in a round bottomed flask. All the solvents were 
anhydride and used without purification. All commercial reagents were obtained from registered 
suppliers and used without further purification.   
6.1.2: Methods and instrumentation: 
Analytical thin-layer chromatography (TLC): This method was used to control the reactions and 
to verify their progress. Thin layers were carried out on DC-Kieselgel ALUGRAM SIL G/UV254 
brand. A solution of phosphomolybdic acid hydrate with ethanol was used as stained. The 
eluent used is specified in each case.  
Column Chromatography: This method was used to purify the different substances obtained in 
each reaction. The stationary phase used was silica gel compacted with hexane. The mobile 
phase is specified in each case, a mixture of a polar and non-polar (or less polar) solvent. The 
column were carried out under low pressure (flash conditions) and performed on 230-400 mesh 
Sigma Aldrich silica gel.  
Nuclear magnetic resonance: 1H NMR, 13C NMR, COSY and HSQC spectra data were collected 
with a Varian 400 spectrometer for the identification of each purified compound. The reference 
compound is specified in each case (ppm). The coupling constant (J) is always in Hz. The 
chemical shifts (δ) are reported in ppm and referenced to internal TMS (δ 0.00 ppm for 1H NMR) or 
CDCl3 (δ 77.00 for 13C NMR). Data are reported as follows: s = singlet, d = doublet, t = triplet, q= 
quartet, m = multiplet, br = broad (and their corresponding combinations). 
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Infrared spectroscopy (IR): This method was used for the characterization of some compounds 
formed during the synthesis. The instrument used is a FTIR Avatar 360 spectrophotometer. 
Only the most relevant peaks (cm-1) are described in the experimental section.  
Specific optical rotation: This method was used for the characterization of some of the pure 
compounds that were not an enantiomer mixture and presented optical rotation. The specific 
rotation ([α]D) were determined at 25 °C on PERKIN ELMER polarimeter 341 polarimeter. They 
are measured on CHCl3 or a 50:50 CHCl3:MeOH solution, and the wavelength used was the D 
line of sodium (589 nm). 
 
6.2. SYNTHESIS OF (2S,3S,E)-CERAMIDE -1,3-PHOSPHODIESTER 
6.2.1. Synthesis of tert-butyl (S)-4-[(S,E)-1-hydroxyhexadec-2-en-1-yl]-2,2-
dimethyloxazolidine-3-carboxylate (11) 
To an ice-cooled stirred suspension of Cp2Zr(H)Cl (1.08 g, 3.75 mmol) in CH2Cl2 (8 mL) 
under argon was added neat 1-pentadecyne (1.02 mL, 3.77 mmol). After stirring at room 
temperature for 20 min, the reaction mixture was cooled to -30ºC and next treated with a 1.0 M 
solution of Et2Zn in hexanes (4.40 mL, 4.40 mmol), followed by aldehyde 10 (873 mg, 3.81 
mmol) in anhydrous CH2Cl2 (2 mL).6,11 The resulting mixture was allowed to warm gradually and 
stirred at rt for 1h. Then, the zirconium salts were precipitated with the addition of 5 mL of 
deionized water and removed by washing with CH2Cl2 in the aqueous phase, filtering with a 
Celite®.8,12 The solution was dried with MgSO4 and filtered. The solvent was removed in vacuo 
and the crude oil was analyzed by 1H NMR to obtain a 15:1 ratio of both two diastereomers of 
11. It was purified by flash column chromatography on silica gel (hexanes/ethyl acetate from 
95:5 to 80:20) to afford 1.39 g (78% yield) of the tert-butyl (S)-4-[(S,E)-1-hydroxyhexadec-2-en-
1-yl]-2,2-dimethyloxazolidine-3-carboxylate (11). 
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White solid; Rf: 0.40 (Hexanes:Ethyl acetate 8:2); 1H 
NMR (400 MHz, CDCl3) δ 5.74 (dt, HOCHCH=CH, J = 
14.2, 6.6 Hz, 1H), 5.41 (m, HOCHCH=CH, 1H), 4.14 
(m, HOCHCH, 1H), 3.98-3.80 (m, CH3COCH2, 2H), 
2.04 (q, CH=CHCH2, J = 6.6 Hz, 2H), 1.58 (s, CH3C(CH3)N, 3H), 1.50 (s, (CH3)3COC(O), 9H), 1.49 (s, 
CH3C(CH3)N, 3H), 1.25 (brs, CH2CH2CH2, 22H), 0.88 (t, CH2CH3, J = 6.6 Hz, 3H). 
 
 
6.2.2. Synthesis of (2S,3S,E)-1,3-dihydroxyoctadec-4-en-2-ammonium chloride (12) 
To a 881 mg (2.07 mmol) of pure 11 in 100 mL of MeOH was added neat acetyl chloride 
(971 μL, 10 mmol) at room temperature. The reaction mixture was stirred for 72 hours. The 
solution was dried with MgSO4 and filtered. The solvent was removed in vacuo and the solid 
was purified by flash column chromatography on silica gel (dichloromethane/methanol from 99:1 
to 88:12) to afford 498 mg (72% yield) of (2S,3S,E)-1,3-dihydroxyoctadec-4-en-2-amonium 
chloride (12).  
White solid; Rf: 0.1 (CH2Cl2:MeOH, 9:1); mp: 68-
70 ºC; [α]D: -10.76 (c 0.97, MeOH); IR: 3295, 
2954, 2917, 2847, 1461, 1461, 970, 724 cm-1. 1H 
NMR (400 MHz, CDCl3) δ 5.83 (dt, HOCHCH=CH, 
J = 15.7, 7.0 Hz, 1H), 5.44 (dd, HOCHCH=CH, J = 15.7, 7.0 Hz, 1H), 4.30 (t, HOCH, J = 7.0 Hz, 1H), 3.87 
(d, HOCH2, J = 11.4 Hz, 2H), 3.45 (m, H3NCH, 1H), 2.02 (q, CHCH2CH2, J = 7.0 Hz, 2H), 1.26 (brs, 
CH2CH2CH2, 22H), 0.88 (t, CH2CH3, J = 7.0 Hz, 3H). 13C NMR (100.6 MHz, CDCl3) δ 137.38, 127.19, 
70.52, 59.34, 58.31, 32.64, 32.10, 29.94, 29.87, 29.77, 29.70, 29.56, 29.26, 22.86, 14.27.  
 
6.2.3. Synthesis of N-[(2S,3S,E)-1,3-dihydroxyoctadec-4-en-2-yl]palmitamide (13) 
EDC (0.39 mL, 2.19 mmol) was added portion wise to a mixture of 405 mg of palmitic acid 
(1.58 mmol) and HOBt (295 mg, 2.19 mmol) in 32 mL of CH2Cl2 under argon atmosphere. After 
stirring for 5 min at room temperature, this solution was added dropwise over a CH2Cl2 solution 
(32 mL) of the sphingoid 12 (1.50 mmol) containing NEt3 (0.45 mL, 3.23 mmol) under argon 
atmosphere. TLC control showed the evolution of the reaction and, after 20 minutes, the 
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solution was washed with 3x10 mL of water, dried with MgSO4 and filtered.13 The solvent was 
removed in vacuo and the solid was purified by flash column chromatography on silica gel 
(dichloromethane/methanol from 99:1 to 97:3). The esters formed during the reaction were 
saponified with a solution of K2CO3 (200 mg) in MeOH (40 mL). After 3 hours, the solvent was 
removed in vacuo and the solid was purified by flash column chromatography on silica gel 
(dichloromethane/methanol from 99:1 to 97:3), to afford 351 mg (45% yield) of the 
corresponding amide 13. 
 
Pink solid; Rf: 0.5 (CH2Cl2:MeOH, 95:5); mp: 97-
100ºC; [α]D : -14.8 (c 0.3, 50:50 MeOH:CHCl3); IR: 
3272, 2955, 2915, 2849, 1645, 1469, 1086, 1049, 
964, 719 cm-1;  1H NMR (400 MHz, CDCl3) δ 6.11 
(d, HNCO, J = 7.0 Hz, 1H), 5.75 (dt, HOCHCH=CH, J = 14.9, 7.0 Hz, 1H), 5.47 (dd, HOCHCH=CH J = 
14.9, 7.0 Hz, 1H), 4.39 (dd, HOCH, J = 3.5, 7.0 Hz, 1H), 3.92 (m, H3NCH, 1H), 3.82 (m, HOCH2, 2H), 2.22 
(t, HNCOCH2, J = 7.0 Hz, 2H), 2.03 (q, CH=CHCH2, J = 7.0 Hz, 2H), 1.63 (q, HNC(O)CH2CH2, J = 7.0 Hz, 
2H), 1.25 (m, CH2CH2CH2, 46H), 0.88 (t, CH2CH3, J = 7.0 Hz, 6H).   
 
6.2.4. Towards the synthesis of N-[(4S,5S)-2-hydroxy-2-oxido-4-((E)-pentadec-1-en-1-yl)-
1,3,2-dioxaphosphinan-5-yl]palmitamide (3) 
6.2.4.1. Synthesis via phosphorus (III)  
6.2.4.1.1. Hydrogenphosphonate addition to the hydroxyl group: synthesis of (2S,3S,E)-3-
hydroxy-2-palmitamidooctadec-4-en-1-yl phosphonate 14,15 (16) 
Imidazole (0.067 g, 0.98 mmol) was dissolved in 4 mL of CH2Cl2 and the solution was kept 
on an ice-water bath (0-5ºC). Phosphorus trichloride (28 μL, 0.32 mmol) was added under 
vigorous stirring, followed by 156 μL (1.12 mmol) of triethylamine. The mixture was stirred for 15 
min and then a solution of ceramide 13 (50 mg, 0.093 mmol) in 4.5 mL of CH2Cl2 was added. 
After the addition was completed, the cooling bath was removed, and the mixture was kept at 
room temperature with continuous stirring for 1h. The reaction mixture was quenched by 2 mL 
of a 0.4 M solution of triethylamine in water at pH 7.5 (using a hydrogencarbonate buffer), 
forming the triethylammonium hydrogenphosphate salt 16. The aqueous salt was washed with 3 
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x 20 mL of CH2Cl2.14 The solvent was removed in vacuo and the solid was purified by flash 
column chromatography on silica gel (dichloromethane/methanol from 95:5 to 85:15) to afford 
73 mg (80% yield) of the phosphonate 16.   
 
White solid. Rf: 0.1 (CH2Cl2:MeOH, 85:15);  
1H NMR: (400 MHz, CD3OH) δ 6.77 (d, 
HP(O)ORO-, J = 633.0 Hz, 1H), 5.78 (m, HN, 
1H), 5.72 (m, HOCHCH=CH, 1H), 5.47 (m, 
HOCHCH=CH, 1H), 4.33 (m, HOCH, 1H), 
4.07 (m, CH(O)NHCH, 1H), 3.97 (m, OPOCH2, 2H), 3.53 (m, OPOCH2, 2H), 3.22 (q, NCH2CH3 (NEt3), J = 
7.3 Hz, 6H), 2.23 (m, HNC(O)CH2, 2H), 2.05 (m, CH=CHCH2, 2H), 1.63 (m, HNC(O)CH2CH2, 2H), 1.35-
1.32 (t, NCH2CH3 (NEt3), 9H), 1.30 (brs, CH2CH2CH2, 46H), 0.91 (t, CH2CH3, J = 7.0 Hz, 6H); 31P RMN: 
(122 MHz, CD3OH) δ 2.20 ppm. 
 
6.2.4.1.2. Cyclization of 16 with pivaloyl chloride: Towards the synthesis of N-[(4S,5S)-2-
hydroxy-2-oxido-4-((E)-pentadec-1-en-1-yl)-1,3,2-dioxaphosphinan-5-yl]palmitamide (3)14,15 
 
To 50 mg of 16 in 3 mL of dry acetonitrile was added at rt 1 mL (12.4 mmol) of dry, freshly 
distilled pyridine under argon atmosphere. Next, 0.39 µL (0.32 mmol) of pivaloyl chloride were 
added dropwise. The solution was stirred by 1 min and 3 mL of dry acetonitrile were added with 
a 5.2 M solution of tert-butyl hydroperoxide in CH2Cl2 to cycle the compound. The reaction 
mixture was dried with MgSO4 and washed 3 times with a triethylamine:water solution 0.7 M. 
The solvent was removed in vacuo and the organic phase was purified by flash column 
chromatography on silica gel (dichloromethane/methanol from 95:5 to 87:13). Traces (8 mg) of 
an unknown compound were isolated 
Rf: 0.1 (85:15 CH2Cl2:MeOH); 31P RMN: (122 MHz, CD3OH) δ 4.86, 3.43 ppm. 
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6.2.4.2. Synthesis via phosphorus(V) 
 
6.2.4.2.1: Synthesis of (2S,3S,E)-3-hydroxy-2-palmitamidooctadec-4-en-1-yl dimethyl 
phosphate (14) 
 
Amide 13 (143 mg, 0.27 mmol) in CH2Cl2 (6 mL) was cooled to 0-5ºC and N-
methylimidazole (180 μL, 2.25 mmol), and then dimethyl chlorophosphate (115 μL, 1.07 mmol) 
were added at same temperature. After the reaction mixture was stirred at rt for 10 min, the 
reaction mixture was quenched by 10 mL of water.15,16 The organic layer was removed in vacuo 
and the solid was purified by flash column chromatography on silica gel 
(dichloromethane/methanol from 95:5 to 20:70) to afford 83 mg (61% yield) of the phosphate 14.  
 
White wax. Rf: 0.50 (CH2Cl2:MeOH, 95:5);  
1H NMR (400 MHz, CDCl3) δ 6.12 (d, 
CONH, J = 7.0 Hz, 1H), 5.75 (dt, 
HOCHCH=CH, J = 15.0, 7.0 Hz, 1H), 5.42 
(dd, HOCHCH=CH, J = 15.0, 7.0 Hz, 1H), 4.37 (m, HOCHCH, 1H), 4.12 – 4.07 (m, OP(O)OCH2, 
OP(O)OCH2CH, 3H), 3.78 (d, CH3OP(CH3), J = 7.7 Hz, 3H), 3.76 (d, CH3OP(CH3), J = 7.7 Hz, 3H), 2.17 (t, 
HNC(O)CH2, J = 7.0 Hz, 2H), 2.01 (q, CH=CHCH2, J = 7.0 Hz, 2H), 1.59 (m, HNCOCH2CH2, 2H), 1.25 
(brs, CH2CH2CH2, 46H), 0.87 (t, CH2CH3, J = 7.0 Hz, 6H); 13C NMR (100.6 MHz, CDCl3) δ 133.93, 128.52, 
77.48, 76.84, 70.00, 65.98, 54.76, 36.86, 32.47, 32.06, 29.84, 29.30, 25.90, 14.25. 
 
 
6.2.4.2.2. Synthesis of (2S,3S,E)-3-hydroxy-2-palmitamidooctadec-4-en-1-yl dihydrogen 
phosphate15,16 (15)  
 
A solution of phosphate 14 (80 mg, 0.125 mmol) in acetonitrile (4.3 mL) was cooled to 0-
5ºC. Iodotrimethylsilane (170 μL, 1.20 mmol) was added to the reaction mixture and stirred at 
room temperature for 2 h.16 Next, 1 mL of saturated sodium thiosulfate solution was added. The 
reaction mixture was stirred for 72 h and treated with 0.1 M aqueous HCl solution until 
neutralization (pH paper). The solvent was removed in vacuo and phosphate 15 was purified by 
flash column chromatography on silica gel (dichloromethane/methanol from 95:5 to 80:15). Only 
traces of compound 15 (8 mg, 10% yield) were isolated.  
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White solid. Rf: 0.1 (CH2Cl2:MeOH, 85:15); 1H 
NMR: (400 MHz, CD3Cl) δ 6.03 – 5.89 (m, CONH, 
1H), 5.89 – 5.69 (m, HOCHCH=CH, 1H), 5.52 – 
5.38 (m, HOCHCH=CH, 1H), 4.32 – 4.25 (m, 
HOCHCH=CH, 1H), 4.19 – 4.02 (m, 
HOP(O)OCH2, 2H), 3.98 – 3.89 (m, HOP(O)OCH2CH, 1H), 3.70 (d, HOP(O)(OH)OCH2,  J = 11.0 Hz, 1H), 
3.61 (d, HOP(O)(OH)OCH2, J =11.0 Hz, 1H), 2.40 (td, NHC(O)CH2, J = 7.0, 2.6 Hz, 2H), 2.23 (m, 
NHC(O)CH2, 2H), 2.11 (q, CH=CHCH2, J = 7.0 Hz, 2H), 2.04 (q, CH=CHCH2, J = 7.0 Hz, 2H), 1.61 (m, 
NHC(O)CH2CH2, 2H), 1.29 (brs, CH2CH2CH2, 46H), 0.90 (t, CH2CH3, J = 7.0 Hz, 6H). 
  




A synthetic approach to the (2S,3S,E)-ceramide-1,3-phosphodiester (3) have been 
developed. However, the yields obtained for the synthetic diastereomer 3 of the natural 
(2S,3R,E)-ceramide-1,3-phosphodiester (9) did not meet the foreseen expectations. Therefore, 
further studies regarding the cyclization reaction to a cyclic phosphate must be reviewed. 
 
• The S configuration of the alcohol and the E configuration of the double bond on Garner’s 
aldehyde (10) was achieved by a syn-selective addition of 1-pentadecyne by a described 
method, allowing a quantitative yield (78%) of tert-butyl (S)-4-[(S,E)-1-hydroxyhexadec-2-en-1-
yl]-2,2-dimethyloxazolidine-3-carboxylate (11). 
• The N-Boc and the N,O-isopropylidene deprotection of the adduct 11 was obtained in 72% 
yield, allowing the subsequent N-acylation of the sphingosine 12 with palmitic acid. The 
(2S,3S,E)-ceramide (13) was obtained in 45% yield. 
• Ceramide 13 was the starting point to test both two phosphorus(III) and phosphorus(V) 
phosphorylation pathways.  
• On the first step of phosphorus(III) synthetic pathway it was obtained the 
hydrogenphosphonate 16 in 80% yield. Unfortunately, the next synthetic step (which would 
allow the desired compound 3) was affected by the oxidation and cyclization of the molecule, 
not providing the desired outcome. 
• The first step of phosphorus(V) synthetic pathway obtained the C1 dimethylphosphate 
adduct 14, in 61% yield. Unfortunately, the deprotection of the phosphonate methyl groups 
regarded a very low yield (10%), thus becoming a non-productive reaction step and preventing 
the continuity on this route. 
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Boc: tert-butyloxycarbonyl  
br: Broad 
C 
13C NMR: carbon nuclear magnetic resonance 
COSY: 1H Correlated spectroscopy 
D 
d: doublet 
dt: double triplet 
E 
EDC: 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide  
H 
1H NMR: proton nuclear magnetic resonance  
HOBt: 1-hydroxybenzotriazole 

















rt: room temperature 
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f) (2S,3S,E)-3-hydroxy-2-palmitamidooctadec-4-en-1-yl dihydrogen phosphate (15): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
